<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://cardiovascres.oxfordjournals.org">
<title>Cardiovascular Research - current issue</title>
<link>http://cardiovascres.oxfordjournals.org</link>
<description>Cardiovascular Research - RSS feed of current issue</description>
<prism:coverDisplayDate>15 July 2008</prism:coverDisplayDate>
<prism:publicationName>Cardiovascular Research</prism:publicationName>
<prism:issn>0008-6363</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-a?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-b?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-c?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-d?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/205?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/208?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/218?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/228?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/238?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/249?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/259?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/269?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/279?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/287?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/294?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/304?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/313?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/322?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/331?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/341?rss=1" />
  <rdf:li rdf:resource="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/352?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP?rss=1">
<title><![CDATA[Editorial Board]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn164</dc:identifier>
<dc:title><![CDATA[Editorial Board]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-a?rss=1">
<title><![CDATA[Contents Page]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-a?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn165</dc:identifier>
<dc:title><![CDATA[Contents Page]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-b?rss=1">
<title><![CDATA[Aims and Scope]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-b?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn166</dc:identifier>
<dc:title><![CDATA[Aims and Scope]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-c?rss=1">
<title><![CDATA[Announcement: Spotlight Issue on Lipid Signalling Pathways in the Heart and Vasculature]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-c?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn167</dc:identifier>
<dc:title><![CDATA[Announcement: Spotlight Issue on Lipid Signalling Pathways in the Heart and Vasculature]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-d?rss=1">
<title><![CDATA[SPOTLIGHT ISSUE ON Signalling in Cardiac Metabolism]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/NP-d?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn168</dc:identifier>
<dc:title><![CDATA[SPOTLIGHT ISSUE ON Signalling in Cardiac Metabolism]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>NP</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>NP</prism:startingPage>
<prism:section>FRONT-MATTER/BACK-MATTER</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/205?rss=1">
<title><![CDATA[Signalling in cardiac metabolism]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/205?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Lopaschuk, G. D., Kelly, D. P.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn134</dc:identifier>
<dc:title><![CDATA[Signalling in cardiac metabolism]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>207</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>205</prism:startingPage>
<prism:section>EDITORIAL</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/208?rss=1">
<title><![CDATA[Transcriptional control of mitochondrial biogenesis: the central role of PGC-1{alpha}]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/208?rss=1</link>
<description><![CDATA[
<p>Although the concept of energy starvation in the failing heart was proposed decades ago, still very little is known about the origin of energetic failure. Recent advances in molecular biology have started to elucidate the transcriptional events governing mitochondrial biogenesis. In particular, a great step was taken with the discovery that peroxisome proliferator-activated receptor gamma co-activator (PGC-1) is the master regulator of mitochondrial biogenesis. The molecular mechanisms underlying the downregulation of PGC-1 and the consequent decrease in mitochondrial function in heart failure are, however, still poorly understood. Indeed, the main pathways involved in mitochondrial biogenesis are thought to be up- rather than down-regulated in pathological hypertrophy and heart failure. The current review summarizes recent advances in this field and is restricted to the heart when cardiac data are available.</p>
]]></description>
<dc:creator><![CDATA[Ventura-Clapier, R., Garnier, A., Veksler, V.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn098</dc:identifier>
<dc:title><![CDATA[Transcriptional control of mitochondrial biogenesis: the central role of PGC-1{alpha}]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>217</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>208</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/218?rss=1">
<title><![CDATA[Genomics in cardiac metabolism]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/218?rss=1</link>
<description><![CDATA[
<p>Cell biology is in transition from reductionism to a more integrated science. Large-scale analysis of genome structure, gene expression, and metabolites are new technologies available for studying cardiac metabolism in diseases known to modify cardiac function. These technologies have several limitations and this review aims both to assess and take a critical look at some important results obtained in genomics restricted to molecular genetics, transcriptomics and metabolomics of cardiac metabolism in pathophysiological processes known to alter myocardial function. Therefore, our goal was to delineate new signalling pathways and new areas of research from the vast amount of data already published on genomics as applied to cardiac metabolism in diseases such as coronary heart disease, heart failure, and ischaemic reperfusion.</p>
]]></description>
<dc:creator><![CDATA[Samuel, J.-L., Schaub, M. C., Zaugg, M., Mamas, M., Dunn, W. B., Swynghedauw, B.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn061</dc:identifier>
<dc:title><![CDATA[Genomics in cardiac metabolism]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>227</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>218</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/228?rss=1">
<title><![CDATA[Diurnal variations in myocardial metabolism]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/228?rss=1</link>
<description><![CDATA[
<p>The heart is challenged by a plethora of extracellular stimuli over the course of a normal day, each of which distinctly influences myocardial contractile function. It is therefore not surprising that myocardial metabolism also oscillates in a time-of-day dependent manner. What is becoming increasingly apparent is that the heart exhibits diurnal variations in its intrinsic properties, including responsiveness to extracellular stimuli. This article summarizes our current knowledge regarding the mechanism(s) mediating diurnal variations in myocardial metabolism. Particular attention is focused towards the intramyocardial circadian clock, a cell autonomous molecular mechanism that appears to regulate myocardial metabolism both directly (e.g. triglyceride and glycogen metabolism) and indirectly (through modulation of the responsiveness of the myocardium to workload, insulin, and fatty acids). In doing so, the circadian clock within the cardiomyocyte allows the heart to anticipate environmental stimuli (such as changes in workload, feeding status) prior to their onset. This synchronization between the myocardium and its environment is enhanced by regular feeding schedules. Conversely, loss of synchronization may occur through disruption of the circadian clock and/or diurnal variations in neurohumoral factors (as observed during diabetes mellitus). Here, we discuss the possibility that loss of synchronization between the heart and its environment predisposes the heart to metabolic maladaptation and subsequent myocardial contractile dysfunction.</p>
]]></description>
<dc:creator><![CDATA[Bray, M. S., Young, M. E.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn054</dc:identifier>
<dc:title><![CDATA[Diurnal variations in myocardial metabolism]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>237</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>228</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/238?rss=1">
<title><![CDATA[Insulin signalling in the heart]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/238?rss=1</link>
<description><![CDATA[
<p>The main role of insulin in the heart under physiological conditions is obviously the regulation of substrate utilization. Indeed, insulin promotes glucose uptake and its utilization via glycolysis. In addition, insulin participates in the regulation of long-chain fatty acid uptake, protein synthesis, and vascular tonicity. Significant advancements have been made over the last 20 years in the understanding of the signal transduction elements involved in these insulin effects. Among these molecular mechanisms, the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway is thought to play a crucial role. Under pathological conditions, such as type-2 diabetes, myocardial ischaemia, and cardiac hypertrophy, insulin signal transduction pathways and action are clearly modified. These molecular signalling alterations are often linked to atypical crosstalks with other signal transduction pathways. On the other hand, pharmacological modifications of parallel and interdependent signalling components, such as the AMP-activated protein kinase pathway, are now considered to be a good therapeutic approach to treat insulin-signalling defects such as insulin resistance and type-2 diabetes. In this review, we will focus on the description of the molecular signalling elements involved in insulin action in the heart and vasculature under these different physiological, pathological, and therapeutical conditions.</p>
]]></description>
<dc:creator><![CDATA[Bertrand, L., Horman, S., Beauloye, C., Vanoverschelde, J.-L.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn093</dc:identifier>
<dc:title><![CDATA[Insulin signalling in the heart]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>248</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>238</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/249?rss=1">
<title><![CDATA[Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/249?rss=1</link>
<description><![CDATA[
<p>Circulating long-chain fatty acids (LCFA) and glucose are the main sources for energy production in the heart. In the healthy heart the ratio of glucose and LCFA oxidation is sensitively balanced and chronic alterations in this substrate mix are closely associated with cardiac dysfunction. While it has been accepted for several years that cardiac glucose uptake is mediated by facilitated transport, i.e. by means of the glucose transport proteins GLUT1 and GLUT4, only in the last few years it has become clear that proteins with high-affinity binding sites to LCFA, referred to as LCFA transporters, are responsible for bulk LCFA uptake. Similar to the GLUTs, the LCFA transporters CD36 and FABP<SUB>pm</SUB> can be recruited from an intracellular storage compartment to the sarcolemma to increase the rate of substrate uptake. Permanent relocation of LCFA transporters, mainly CD36, from intracellular stores to the sarcolemma is accompanied by accumulation of lipids and lipid metabolites in the heart. As a consequence, insulin signalling and glucose utilization are impaired, leading to decreased contractile activity of the heart. These observations underline the particular role and interplay of substrate carriers for glucose and LCFA in modulating cardiac metabolism, and the development of heart failure. The signalling and trafficking pathways and subcellular machinery regulating translocation of glucose and LCFA transporters are beginning to be unravelled. More knowledge on substrate transporter recycling, especially the similarities and differences between glucose and LCFA transporters, is expected to enable novel therapies aimed at changing the subcellular distribution of glucose and LCFA transporters, thereby manipulating the substrate preference of the diseased heart to help restore cardiac function.</p>
]]></description>
<dc:creator><![CDATA[Schwenk, R. W., Luiken, J. J.F.P., Bonen, A., Glatz, J. F.C.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn116</dc:identifier>
<dc:title><![CDATA[Regulation of sarcolemmal glucose and fatty acid transporters in cardiac disease]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>258</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>249</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/259?rss=1">
<title><![CDATA[The malonyl CoA axis as a potential target for treating ischaemic heart disease]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/259?rss=1</link>
<description><![CDATA[
<p>Cardiovascular disease is the leading cause of death and disability for people living in western societies, with ischaemic heart disease accounting for the majority of this health burden. The primary treatment for ischaemic heart disease consists of either improving blood and oxygen supply to the heart or reducing the heart&rsquo;s oxygen demand. Unfortunately, despite recent advances with these approaches, ischaemic heart disease still remains a major health problem. Therefore, the development of new treatment strategies is still required. One exciting new approach is to optimize cardiac energy metabolism, particularly by decreasing the use of fatty acids as a fuel and by increasing the use of glucose as a fuel. This approach is beneficial in the setting of ischaemic heart disease, as it allows the heart to produce energy more efficiently and it reduces the degree of acidosis associated with ischaemia/reperfusion. Malonyl CoA is a potent endogenous inhibitor of cardiac fatty acid oxidation, secondary to inhibiting carnitine palmitoyl transferase-I, the rate-limiting enzyme in the mitochondrial uptake of fatty acids. Malonyl CoA is synthesized in the heart by acetyl CoA carboxylase, which in turn is phosphorylated and inhibited by 5'AMP-activated protein kinase. The degradation of myocardial malonyl CoA occurs via malonyl CoA decarboxylase (MCD). Previous studies have shown that inhibiting MCD will significantly increase cardiac malonyl CoA levels. This is associated with an increase in glucose oxidation, a decrease in acidosis, and an improvement in cardiac function and efficiency during and following ischaemia. Hence, the malonyl CoA axis represents an exciting new target for the treatment of ischaemic heart disease.</p>
]]></description>
<dc:creator><![CDATA[Ussher, J. R., Lopaschuk, G. D.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn130</dc:identifier>
<dc:title><![CDATA[The malonyl CoA axis as a potential target for treating ischaemic heart disease]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>268</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>259</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/269?rss=1">
<title><![CDATA[Role of diet and fuel overabundance in the development and progression of heart failure]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/269?rss=1</link>
<description><![CDATA[
<p>Under physiological conditions, the human heart derives energy from glucose, fatty acids, and/or lactate depending upon substrate availability, circulating hormone levels, and nutritional status. Circulating free fatty acid and glucose levels often exceed the normal range, as observed with type 2 diabetes, obesity, or physical inactivity. Chronic exposure of the heart to high plasma levels of free fatty acids may cause accumulation of toxic lipid intermediates within cardiomyocytes. Furthermore, suppression of glucose oxidation by increased fatty acid uptake shunts glucose into the oxidative pentose phosphate and hexosamine biosynthetic pathways, both of which yield potentially harmful products. Noxious derivatives of aberrant glucose and fatty acid oxidation can activate signalling cascades leading to myocyte dysfunction or death, processes termed &lsquo;glucotoxicity&rsquo; and &lsquo;lipotoxicity&rsquo;. This review discusses the effects of dietary extremes (e.g. high fat and high carbohydrate consumption) and substrate overabundance in the context of heart failure (HF) development and progression. Emerging data suggest that substrate excess leads to cardiac dysfunction and HF, which may be prevented or slowed by maintaining low body fat and high insulin sensitivity and consuming a diet of low glycaemic load that is high in mono- and polyunsaturated fatty acids.</p>
]]></description>
<dc:creator><![CDATA[Chess, D. J., Stanley, W. C.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn074</dc:identifier>
<dc:title><![CDATA[Role of diet and fuel overabundance in the development and progression of heart failure]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>278</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>269</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/279?rss=1">
<title><![CDATA[Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/279?rss=1</link>
<description><![CDATA[
<p>Adipokines represent a family of proteins released by adipocytes that affect various biological processes including metabolism, satiety, inflammation, and cardiovascular function. The first adipokine to be identified is leptin, a product of the obesity gene whose primary function is to act as a satiety factor. However, it is now recognized that leptin and many of the newly discovered adipokines produce effects on numerous organ systems including the heart. Indeed, various adipokines including leptin, adiponectin, and apelin exert potent and diverse cardiovascular effects which are mediated by their specific receptors and involve complex and multifaceted cell-signalling pathways. Among these are effects on the heart as well as blood pressure where leptin has been proposed to potentially contribute to obesity-related hypertension. In this review, we focus primarily on the diverse effects of adipokines on the heart and discuss the potential cell-signalling mechanisms underlying their actions. The potential role of adipokines in the regulation of cardiac metabolism and function is discussed. Discussion is also presented on the emerging role, both deleterious and salutary, of various adipokines in heart disease with an examination of the possible underlying mechanisms which contribute to these effects.</p>
]]></description>
<dc:creator><![CDATA[Karmazyn, M., Purdham, D. M., Rajapurohitam, V., Zeidan, A.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn115</dc:identifier>
<dc:title><![CDATA[Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>286</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>279</prism:startingPage>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/287?rss=1">
<title><![CDATA[LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/287?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>Collagen, as a component of the extracellular matrix, has been linked to atherosclerotic plaque formation and stability. Activation of LOX-1, a lectin-like oxidized low-density lipoprotein (LDL) receptor-1, exerts a significant role in collagen formation. We examine the hypothesis that LOX-1 deletion may inhibit collagen accumulation in atherosclerotic arteries in LDL receptor (LDLR) knockout (KO) mice.</p>
</sec>
<sec><st>Methods and results</st>
<p>We generated LOX-1 KO and LOX-1/LDLR double KO mice on a C57BL/6 (wild-type mice) background and fed a 4% cholesterol/10% cocoa butter diet for 18 weeks. Vessel wall collagen accumulation was increased in association with atherogenesis in the LDLR KO mice (<I>P</I> &lt; 0.01 vs. wild-type mice), but much less so in the double KO mice (<I>P</I> &lt; 0.01 vs. LDLR KO mice). Collagen accumulation data were corroborated with pro-collagen I measurements. Expression/activity of osteopontin, fibronectin, and matrix metalloproteinases (MMP-2 and MMP-9) was also increased in the LDLR KO mice (<I>P</I> &lt; 0.01 vs. wild-type mice), but not in the mice with LOX-1 deletion (<I>P</I> &lt; 0.01 vs. LDLR KO mice). The expression of NADPH oxidase (p47<sup>phox</sup>, p22<sup>phox</sup>, gp91<sup>phox</sup>, and Nox-4 subunits) and nitrotyrosine was increased in the LDLR KO mice (<I>P</I> &lt; 0.01 vs. wild-type mice) and not in mice with LOX-1 deletion (<I>P</I> &lt; 0.01 vs. LDLR KO mice). Phosphorylation of Akt-1 and endothelial nitric oxide synthase and expression of haem-oxygenase-1 were found to be reduced in the LDLR KO mice (<I>P</I> &lt; 0.01 vs. wild-type mice), but not in the mice with LOX-1 deletion (<I>P</I> &lt; 0.01 vs. LDLR KO mice).</p>
</sec>
<sec><st>Conclusion</st>
<p>LOX-1 deletion reduces enhanced collagen deposition and MMP expression in atherosclerotic regions via inhibition of pro-oxidant signals.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Hu, C., Dandapat, A., Sun, L., Chen, J., Marwali, M. R., Romeo, F., Sawamura, T., Mehta, J. L.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn110</dc:identifier>
<dc:title><![CDATA[LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>293</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>287</prism:startingPage>
<prism:section>ORIGINAL ARTICLES</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/294?rss=1">
<title><![CDATA[Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/294?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>Postprandial triglyceride-rich lipoproteins (TRL) have a direct effect on vascular smooth muscle cells (SMC) and they increase the risk of atherogenesis. Here, we have tested the hypothesis that the different fatty acid composition of TRL is capable of differentially modifying gene expression in human coronary artery SMC (CASMC). In addition, the effect of TRL on cell proliferation and transcription factor activation was also evaluated.</p>
</sec>
<sec><st>Methods and results</st>
<p>TRL were prepared from plasma of healthy volunteers after the ingestion of meals enriched in refined olive oil (ROO), butter or a mixture of vegetable and fish oils (VEFO). We use cDNA microarrays to determine the genes differentially expressed in TRL-treated CASMC. Correspondence cluster analysis demonstrated that TRL-butter, -ROO and -VEFO provoked different transcriptional profiles in CASMC. Sixty-six genes were regulated by TRL-butter, 55 by &ndash;ROO, and 47 by -VEFO. The data revealed that TRL-butter predominantly activated genes involved in the regulation of cell proliferation and inflammation. Likewise, TRL-VEFO induced the expression of genes implicated in inflammation, while TRL-ROO promoted a less atherogenic gene profile.</p>
</sec>
<sec><st>Conclusion</st>
<p>The pathophysiological contribution of TRL to the development of atherosclerosis and the stability of atherosclerotic plaques may depend on the fatty acid composition of TRL. Our findings suggest a role for macrophage-inhibiting cytokine-1 (MIC-1) in coronary artery cardiovascular events.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Bermudez, B., Lopez, S., Pacheco, Y. M., Villar, J., Muriana, F. J.G., Hoheisel, J. D., Bauer, A., Abia, R.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn082</dc:identifier>
<dc:title><![CDATA[Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>303</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>294</prism:startingPage>
<prism:section>ORIGINAL ARTICLES</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/304?rss=1">
<title><![CDATA[Vascular tolerance to nitroglycerin in ascorbate deficiency]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/304?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>Nitroglycerin (GTN) acts through release of a nitric oxide (NO)-related activator of soluble guanylate cyclase in vascular smooth muscle. Besides enzymatic GTN bioactivation catalysed by aldehyde dehydrogenase, non-enzymatic reaction of GTN with ascorbate also results in the formation of a bioactive product. Using an established guinea pig model of ascorbate deficiency, we investigated whether endogenous ascorbate contributes to GTN-induced vasodilation.</p>
</sec>
<sec><st>Methods and results</st>
<p>Guinea pigs were fed either standard or ascorbate-free diet for 2 or 4 weeks prior to measuring the GTN response of aortic rings and isolated hearts. The effects of ascorbate on GTN metabolism were studied with purified mitochondrial aldehyde dehydrogenase (ALDH2) and isolated mitochondria. Ascorbate deprivation led to severe scorbutic symptoms and loss of body weight, but had no (2 weeks) or only slight (4 weeks) effects on aortic relaxations to a direct NO donor. The EC<SUB>50</SUB> of GTN was increased from 0.058 &plusmn; 0.018 to 0.46 &plusmn; 0.066 and 5.5 &plusmn; 0.9 &micro;M after 2 and 4 weeks of ascorbate-free diet, respectively. Similarly, coronary vasodilation to GTN was severely impaired in ascorbate deficiency. The potency of GTN was reduced to a similar extent by ALDH inhibitors in control and ascorbate-deficient blood vessels. Up to 10 mM ascorbate had no effect on GTN metabolism catalysed by purified ALDH2 or liver mitochondria isolated from ascorbate-deficient guinea pigs.</p>
</sec>
<sec><st>Conclusion</st>
<p>Our results indicate that prolonged ascorbate deficiency causes tolerance to GTN without affecting NO/cyclic GMP-mediated vasorelaxation.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Wolkart, G., Wenzl, M. V., Beretta, M., Stessel, H., Schmidt, K., Mayer, B.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn107</dc:identifier>
<dc:title><![CDATA[Vascular tolerance to nitroglycerin in ascorbate deficiency]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>312</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>304</prism:startingPage>
<prism:section>ORIGINAL ARTICLES</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/313?rss=1">
<title><![CDATA[Ethanol stimulates endothelial cell angiogenic activity via a Notch- and angiopoietin-1-dependent pathway]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/313?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>Our aims were to determine the effect of alcohol (EtOH) on endothelial angiogenic activity and to delineate the cell signalling mechanisms involved.</p>
</sec>
<sec><st>Methods and results</st>
<p>Treatment of human umbilical vein endothelial cells (HUVECs) with EtOH (1&ndash;100 mM, 24 h) dose-dependently increased their network formation on Matrigel (an index of angiogenesis) with a maximum response (2.5- to 3-fold increase) at 25 mM. Ethanol also stimulated the proliferation (by cell count and proliferating cell nuclear antigen expression) and migration (by scratch wound assay) of HUVECs. In parallel cultures, EtOH stimulated Notch receptor (1 and 4) and Notch target gene (hrt-1, -2, and -3) mRNA and protein expression and enhanced CBF-1/RBP-Jk promoter activity. EtOH also stimulated, at the mRNA and protein level, the expression of angiopoietin-1 (Ang1) and its Tie2 receptor in these cells. Knockdown of Notch 1 or 4 by siRNA or inhibition of Notch-mediated, CBF-1/RBP-Jk-regulated gene expression by the Epstein&ndash;Barr virus-encoded protein RPMS-1 inhibited both ethanol-induced Ang1/Tie2 expression in HUVECs and their network formation on Matrigel. Moreover, knockdown of Ang1 or Tie2 by siRNA inhibited ethanol-induced endothelial network formation.</p>
</sec>
<sec><st>Conclusion</st>
<p>These data demonstrate that ethanol, at levels consistent with moderate consumption, enhances endothelial angiogenic activity <I>in vitro</I> by stimulating a novel Notch/CBF-1/RBP-JK&ndash;Ang1/Tie2-dependent pathway. These actions of ethanol may be relevant to the cardiovascular effects of alcohol consumption purported by epidemiological studies.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Morrow, D., Cullen, J. P., Cahill, P. A., Redmond, E. M.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn108</dc:identifier>
<dc:title><![CDATA[Ethanol stimulates endothelial cell angiogenic activity via a Notch- and angiopoietin-1-dependent pathway]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>321</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>313</prism:startingPage>
<prism:section>ORIGINAL ARTICLES</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/322?rss=1">
<title><![CDATA[Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/322?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>Recent studies from our laboratory demonstrated that increased expression of the small GTP-binding protein RhoA and activation of the RhoA/rho kinase (ROCK) pathway play an important role in the contractile dysfunction associated with diabetic cardiomyopathy in hearts from streptozotocin (STZ)-induced diabetic rats. Nitric oxide (NO) has been reported to be a positive regulator of RhoA expression in vascular smooth muscle, and we have previously found that the expression of inducible NO synthase (iNOS) is increased in hearts from STZ-diabetic rats. Therefore, in this study, we investigated the hypothesis that induction of iNOS positively regulates RhoA expression in diabetic rat hearts.</p>
</sec>
<sec><st>Methods and results</st>
<p>To determine whether NO and iNOS could increase RhoA expression in the heart, cardiomyocytes from non-diabetic rats were cultured in the presence of the NO donor sodium nitroprusside (SNP) or lipopolysaccharide (LPS) in the absence and presence of the selective iNOS inhibitor, <I>N</I><sup>6</sup>-(1-iminoethyl)-<scp>l</scp>-lysine dihydrochloride (L-NIL). In a second study, 1 week after induction of diabetes with STZ, rats were treated with L-NIL (3 mg/kg/day) for 8 more weeks to determine the effect of iNOS inhibition <I>in vivo</I> on RhoA expression and cardiac contractile function. Expression of iNOS was elevated in cardiomyocytes isolated from diabetic rat hearts. Both SNP and LPS increased RhoA expression in non-diabetic cardiomyocytes. The LPS-induced elevation in RhoA expression was accompanied by an increase in iNOS expression and prevented by L-NIL. Treatment of diabetic rats with L-NIL led to a significant improvement in left ventricular developed pressure and rates of contraction and relaxation concomitant with normalization of total cardiac nitrite levels, RhoA expression, and phosphorylation of the ROCK targets LIM (Lin-11, Isl-1, Mec-3) kinase and ezrin/radixin/moesin.</p>
</sec>
<sec><st>Conclusion</st>
<p>These data suggest that iNOS is involved in the increased expression of RhoA in diabetic hearts and that one of the mechanisms by which iNOS inhibition improves cardiac function is by preventing the upregulation of RhoA and its availability for activation.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Soliman, H., Craig, G. P., Nagareddy, P., Yuen, V. G., Lin, G., Kumar, U., McNeill, J. H., MacLeod, K. M.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn095</dc:identifier>
<dc:title><![CDATA[Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>330</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>322</prism:startingPage>
<prism:section>ORIGINAL ARTICLES</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/331?rss=1">
<title><![CDATA[Enhanced acyl-CoA dehydrogenase activity is associated with improved mitochondrial and contractile function in heart failure]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/331?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>Heart failure is associated with decreased myocardial fatty acid oxidation capacity and has been likened to energy starvation. Increased fatty acid availability results in an induction of genes promoting fatty acid oxidation. The aim of the present study was to investigate possible mechanisms by which high fat feeding improved mitochondrial and contractile function in heart failure.</p>
</sec>
<sec><st>Methods and results</st>
<p>Male Wistar rats underwent coronary artery ligation (HF) or sham surgery and were immediately fed either a normal (14% kcal fat) (SHAM, HF) or high-fat diet (60% kcal saturated fat) (SHAM+FAT, HF+FAT) for 8 weeks. Mitochondrial respiration and gene expression and enzyme activities of fatty acid-regulated mitochondrial genes and proteins were assessed. Subsarcolemmal (SSM) and interfibrillar mitochondria were isolated from the left ventricle. State 3 respiration using lipid substrates octanoylcarnitine and palmitoylcarnitine increased in the SSM of HF+FAT compared with SHAM+FAT and HF, respectively (242 &plusmn; 21, 246 &plusmn; 21 vs. 183 &plusmn; 8, 181 &plusmn; 6 and 193 &plusmn; 17, 185 &plusmn; 16 nAO min<sup>&ndash;1</sup> mg<sup>&ndash;1</sup>). Despite decreased medium-chain acyl-CoA dehydrogenase (MCAD) mRNA in HF and HF+FAT, MCAD protein was not altered, and MCAD activity increased in HF+FAT (HF, 65.1 &plusmn; 2.7 vs. HF+FAT, 81.5 &plusmn; 5.4 nmoles min<sup>&ndash;1</sup> mg<sup>&ndash;1</sup>). Activities of short- and long-chain acyl-CoA dehydrogenase also were elevated and correlated to increased state 3 respiration. This was associated with an improvement in myocardial contractility as assessed by left ventricular +d<I>P</I>/d<I>t</I> max.</p>
</sec>
<sec><st>Conclusion</st>
<p>Administration of a high-fat diet increased state 3 respiration and acyl-CoA dehydrogenase activities, but did not normalize mRNA or protein levels of acyl-CoA dehydrogenases in coronary artery ligation-induced heart failure rats.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Rennison, J. H., McElfresh, T. A., Okere, I. C., Patel, H. V., Foster, A. B., Patel, K. K., Stoll, M. S., Minkler, P. E., Fujioka, H., Hoit, B. D., Young, M. E., Hoppel, C. L., Chandler, M. P.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn066</dc:identifier>
<dc:title><![CDATA[Enhanced acyl-CoA dehydrogenase activity is associated with improved mitochondrial and contractile function in heart failure]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>340</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>331</prism:startingPage>
<prism:section>ORIGINAL ARTICLES</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/341?rss=1">
<title><![CDATA[Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/341?rss=1</link>
<description><![CDATA[
<sec><st>Aims</st>
<p>One of the main causes of cardiovascular complications in diabetes is the hyperglycaemia-induced cell injury, and mitochondrial fission has been implicated in the apoptotic process. We investigated the role of mitochondrial fission in high glucose-induced cardiovascular cell injury.</p>
</sec>
<sec><st>Methods and results</st>
<p>We used several types of cultured mouse, rat, and bovine cells from the cardiovascular system, and evaluated mitochondrial morphology, reactive oxygen species (ROS) levels, and apoptotic parameters in sustained high glucose incubation. Adenoviral infection was used for the inhibition of the fission protein DLP1. We found that mitochondria were short and fragmented in cells incubated in sustained high glucose conditions. Under the same conditions, cellular ROS levels were high and cell death was increased. We demonstrated that the increased level of ROS causes mitochondrial permeability transition (MPT), phosphatidylserine exposure, cytochrome <I>c</I> release, and caspase activation in prolonged high glucose conditions. Importantly, maintaining tubular mitochondria by inhibiting mitochondrial fission in sustained high glucose conditions normalized cellular ROS levels and prevented the MPT and subsequent cell death. These results demonstrate that mitochondrial fragmentation is an upstream factor for ROS overproduction and cell death in prolonged high glucose conditions.</p>
</sec>
<sec><st>Conclusion</st>
<p>These findings indicate that the fission-mediated fragmentation of mitochondrial tubules is causally associated with enhanced production of mitochondrial ROS and cardiovascular cell injury in hyperglycaemic conditions.</p>
</sec>
]]></description>
<dc:creator><![CDATA[Yu, T., Sheu, S.-S., Robotham, J. L., Yoon, Y.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn104</dc:identifier>
<dc:title><![CDATA[Mitochondrial fission mediates high glucose-induced cell death through elevated production of reactive oxygen species]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>351</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>341</prism:startingPage>
<prism:section>ORIGINAL ARTICLES</prism:section>
</item>

<item rdf:about="http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/352?rss=1">
<title><![CDATA[Corrigendum to: Altered Na+/Ca2+-exchanger activity due to downregulation of Na+/K+-ATPase {alpha}2-isoform in heart failure]]></title>
<link>http://cardiovascres.oxfordjournals.org/cgi/content/short/79/2/352?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Swift, F., Birkeland, J. A. K., Tovsrud, N., Enger, U. H., Aronsen, J. M., Louch, W. E., Sjaastad, I., Sejersted, O. M.]]></dc:creator>
<dc:date>2008-07-01</dc:date>
<dc:identifier>info:doi/10.1093/cvr/cvn147</dc:identifier>
<dc:title><![CDATA[Corrigendum to: Altered Na+/Ca2+-exchanger activity due to downregulation of Na+/K+-ATPase {alpha}2-isoform in heart failure]]></dc:title>
<dc:publisher>European Society of Cardiology</dc:publisher>
<prism:number>2</prism:number>
<prism:volume>79</prism:volume>
<prism:endingPage>352</prism:endingPage>
<prism:publicationDate>2008-07-15</prism:publicationDate>
<prism:startingPage>352</prism:startingPage>
<prism:section>CORRIGENDUM</prism:section>
</item>

</rdf:RDF>